Holen Sie sich die Stockscreener-App
12.47
0.32%
0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$12.43
Offen:
$12.43
24-Stunden-Volumen:
787.33K
Relative Volume:
0.35
Marktkapitalisierung:
$1.61B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-20.11
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
-1.34%
1M Leistung:
+1.55%
6M Leistung:
+98.25%
1J Leistung:
-17.09%
1-Tages-Spanne:
$12.04
$12.67
1-Wochen-Bereich:
$12.04
$13.29
52-Wochen-Spanne:
$4.72
$15.32
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
12.47 | 1.61B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
US Stocks Recap: Can NeoGenomics Inc deliver alphaJuly 2025 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - BioSpace
NeoGenomics: Distribution Moat In Community Oncology (NASDAQ:NEO) - Seeking Alpha
Should NeoGenomics’ CFO Transition and Early 2025 Revenue Signals Require Action From NEO Investors? - simplywall.st
Published on: 2026-01-25 10:30:50 - baoquankhu1.vn
Don't Ignore The Insider Selling In NeoGenomics - Sahm
NeoGenomics (NASDAQ:NEO) COO Sells 22,128 Shares of Stock - MarketBeat
Neogenomics pres. Stone sells $277k in NEO stock By Investing.com - Investing.com Nigeria
Neogenomics pres. Stone sells $277k in NEO stock - Investing.com
Anatomic Pathology Market Innovations and Key Players: Agilent - openPR.com
Volume Report: Why is NeoGenomics Inc stock going upEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
NeoGenomics, Inc. (NEO) Stock Analysis: Unpacking a 12.81% Upside Potential Amidst Healthcare Diagnostics Growth - DirectorsTalk Interviews
Is NeoGenomics Inc. stock overvalued or fairly pricedFinancial Sector Performance & Target Triple-Digit Stock Opportunities - bollywoodhelpline.com
Aug Sentiment: Why is NeoGenomics Inc stock going upRate Cut & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
How NeoGenomics’ (NEO) CFO Transition and Double‑Digit Revenue Guidance Has Changed Its Investment Story - simplywall.st
Pullback Watch: Should you buy the dip on NeoGenomics IncJuly 2025 Trade Ideas & Smart Swing Trading Alerts - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Raised to Strong-Buy at Zacks Research - MarketBeat
What’s the analyst consensus on NeoGenomics Inc.2025 Pullback Review & Weekly Sector Rotation Insights - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
Aug Volume: Is NeoGenomics Inc stock undervalued right nowQuarterly Profit Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
NeoGenomics names incoming CFO amid revenue growth - Gulfshore Business
NeoGenomics, Inc. (NEO) Stock Analysis: Assessing A 16.59% Potential Upside - DirectorsTalk Interviews
NeoGenomics forecasts 11% revenue growth for Q4 2025, names new CFO - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Down 7.4%Here's What Happened - MarketBeat
NeoGenomics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
NeoGenomics, Inc. Announces Executive Changes - marketscreener.com
Fort Myers-based NeoGenomics expects big revenue increase for 2025 - news-press.com
NeoGenomics (NASDAQ:NEO) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - The National Law Review
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue - PharmiWeb.com
NeoGenomics sees Q4 revenue of about $190M - MSN
NeoGenomics prelim Q4 revenue slightly beats estimates, names insider as CFO - TradingView
NeoGenomics announces board changes to support future growth - MSN
How NeoGenomics Inc. stock reacts to oil prices2025 Biggest Moves & Weekly Return Optimization Plans - Улправда
Will NeoGenomics Inc. stock attract more institutional investorsMarket Risk Analysis & Daily Risk Controlled Trade Plans - Улправда
Will NeoGenomics Inc. stock benefit from infrastructure spending2025 Macro Impact & Fast Moving Trade Plans - Улправда
Neogenomics Shares Surge on Strategic and Legal Developments - AD HOC NEWS
Will NeoGenomics Inc. stock outperform international peersQuarterly Market Summary & Smart Money Movement Alerts - Улправда
A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift - Yahoo Finance
NeoGenomics, Inc. (NEO) Investor Outlook: Diagnostic Leader With 18% Upside Potential - DirectorsTalk Interviews
NeoGenomics to Present at 44th Annual J.P. Morgan Healthcare Conference - Intellectia AI
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
HighMark Wealth Management LLC Has $3.09 Million Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Announces Board Changes to Support Future Growth - The Globe and Mail
NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com - Investing.com Nigeria
NeoGenomics, Inc. (NEO) Stock Analysis: Exploring a 13% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):